Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found a high prevalence of central hair loss among African American women and associated it with diabetes mellitus type 2, bacterial scalp infections, and hairstyles causing traction.

This study evaluated the quality of androgenetic alopecia guidelines using the AGREE II instrument and found the European guideline to be the highest-rated, while American guidelines required modifications.

This study found that blood cell count derived parameters were similar across non-cicatricial alopecia groups but showed general differences when compared to psoriasis and hidradenitis suppurativa. Among patients with alopecia areata, modulating platelet number and volume may serve as a therapeutic marker.

In this ongoing phase 3 study, ritlecitinib demonstrated sustained efficacy up to 24 months in patients aged 12 or older with alopecia areata, showing increased response rates with or without an initial loading dose and supporting its long-term use.

In this study, researchers identified a novel genetic variant in the NR3C1 gene in a mother and her son that predicts a truncated protein, leading to glucocorticoid resistance syndrome with mild hyperandrogenic features, although no clear genotype-phenotype correlation has been established.

This study identified risk of harm and set of competency and skills as key criteria in defining the profession of allied health in Malaysia, highlighting the need for integrated criteria in healthcare policy development.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This paper describes the development of diagnostic criteria for several enduring sexual dysfunction conditions following the use of certain medications, highlighting common sexual and non-sexual symptoms.

This study introduced the KRDQN predictive framework, which outperformed existing methods in predicting adverse drug reactions and provided interpretable insights into drug mechanisms, aiding pharmacovigilance and clinical decision-making.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

This discussion proposes a model to incorporate patients with hormone-resistant prostate cancer into the existing framework by redefining hormone resistance and exploring new therapeutic approaches.

This proof-of-concept study reported that a new, ultra-fast, one-step immunohistochemistry method improved the interpretation of Mohs surgery slides, particularly for poorly differentiated tumors.

In this case study, a 53-year-old male diagnosed with Cronkhite-Canada syndrome saw improvements in diarrhea and hair regrowth after starting treatment with prednisolone, and a year later, all polyps had disappeared, suggesting a potential link between the syndrome and Alopecia areata incognita.

This study found that cortisone reductase deficiency is caused by inactivating mutations in the H6PD gene, affecting cortisol metabolism by preventing 11β-HSD1 enzyme function.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

In this review, the authors highlight the involvement of the 5α-reductase enzyme family in androgen-dependent disorders, noting the discovery of a novel isoform, SRD5A3, which is overexpressed in cancers with poor prognosis.

This study reports a novel diagnostic method for latent circadian rhythm sleep-wake disorder using circadian gene oscillations from hair follicle cells to improve sleep disorder differentiation and potential therapeutic intervention.

In this study, the MPV/PC ratio was identified as a potential tool for assessing disease activity in alopecia areata, with higher ratios in active and severe cases compared to inactive and mild/moderate ones.

This chapter discusses the synthesis and analysis of near-infrared fluorescent activity-based probes for imaging cysteine protease activity, reporting potential benefits for disease diagnosis but noting challenges in imaging specific locations with high cathepsin activity.

In this study, trichoscopy was used to diagnose female androgenic alopecia with 92% specificity by identifying specific hair and scalp patterns.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

This review discusses the importance of androgen production and metabolism in hyperandrogenism, the use of specific serum markers for diagnosis, and the need for improved assays for clinical testing, but reports no new results.

This letter to the editors discusses the nature of alopecia in Cronkhite–Canada syndrome and questions whether it is truly telogen effluvium, but it reports no new clinical findings.

This review discusses various applications of CRISPR-based tools in cancer research, emphasizing their potential for investigating microRNA functions and developing microRNA-based therapies, despite challenges like off-target effects and delivery issues in using CRISPR/Cas9.

This review emphasizes the importance of considering race and ethnicity-specific factors in diagnosing and treating polycystic ovary syndrome (PCOS) and calls for diagnostic criteria tailored to these differences.

This article provides no abstract or new research findings; it appears to be a citation entry without detailed content.

This review highlights that deucravacitinib, a selective TYK2 inhibitor, shows promise as an effective treatment for psoriasis and other inflammatory skin diseases, though real-world evidence beyond psoriasis is still emerging.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

This study identified female sex and specific radiological findings as risk factors for chronic post-COVID syndrome, while long-term use of angiotensin-2 receptor blockers was linked to fewer chronic symptoms.